TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial


Elisabeth Quoix, et al.
The Lancet Oncology, December 2015, 17: 212–23 – Download the article
Publication